Abstract
Long-term results of precuffed expanded polytetrafluoroethylene (ePTFE) grafts used for peripheral bypass surgery are lacking. The aim of this study was to obtain the long-term outcomes of precuffed ePTFE grafts compared with autologous saphenous vein (ASV) grafts used in patients with peripheral arterial disease (PAD). A single-institution retrospective study of precuffed ePTFE and ASV graft performances in patients with PADwas undertaken between January 2004 and December 2012. Five-year primary patency, secondary patency, and limb salvage rates were determined by Kaplan-Meier analyses. A total of 467 bypass grafts were included in this study (169 precuffed ePTFE grafts and 298 ASV grafts). Secondary patency rates of ePTFE vs ASV at 1 and 5years, respectively, were as follows: for 134 supragenicular femoropopliteal bypasses, 60% and 27% vs 89% and 85% (P< .05); for 190 infragenicular femoropopliteal bypasses, 40% and 25% vs 86% and 79% (P< .05); and for 84 femorocrural bypasses, 30% and 14% vs 50% and 50% (P< .05). Five-year limb salvage rates of ePTFE vs ASV for supragenicular femoropopliteal bypasses were 82% vs 94% (P= .16); for infragenicular femoropopliteal bypasses, 41% vs 92% (P< .05); and for femorocrural bypasses, 43% vs 64% (P= .06). ASV bypasses are still the first-choice conduit in peripheral bypass surgery performed in patients with PAD.Precuffed ePTFE bypasses are acceptable alternatives in the absence of adequate autologous vein.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.